08
2018-05
Proxalutamide Tablet Phase III Clinical Trials Investigator Meeting Was Held Successfully
On May 6, 2018, Proxalutamide Tablet Phase III Clinical Trials Investigator Meeting attracting participation of more than 30 hospitals was successfully held at Hyatt Hotel in Suzhou, symbolizing the official start of the first phase III clinical trials of Suzhou Kintor.
24
2018-01
(January 24, 2018, Suzhou) Suzhou Kintor Pharmaceuticals, Inc. (hereinafter referred to as "Suzhou Kintor") and Pfizer Inc. (“Pfizer”) held a press conference on the development project of innovative antibody drug for cancer in Suzhou today. Under the agreement, Pfizer will grant Suzhou Kintor the exclusive license to develop, produce and commercialize an innovative antibody drug for cancer globally. This is the first time that Pfizer has authorized the license to develop innovative antibody drug to a local Chinese enterprise. The drug is also expected to become the world's first fully human therapeutic monoclonal antibody against Activin receptor-like kinase-1 (ALK-1) target.
11
2018-01
On January 11, 2018, Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") announced the completion of Series C investment of RMB 288 million. This round of investment was led by Green Pine Capital Partnership, and followed by Orient Securities Capital Investment, Hangzhou Betta Capital, CCB Investment, and Shanghai Broad Resources, etc.
17
2015-07
Recently, a new-generation AR antagonist, proxalutamide, independently developed by Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") receives initiation funding for special project of significant novel drugs development in "13th Five-Year plan".
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn